PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

NCT Number	NCT07472140
Lead Sponsor	N.N. Alexandrov National Cancer Centre
Conditions	Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer
Enrollment	120 participants
Start Date	2025-07-01
Primary Completion	2033-06-30 (estimated)
Study Completion	2033-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-16